phrykt

Atara Biotherapeutics, Inc. (ATRA): who owns it and who trades it

As of Nov 16, 2026, ATRA insiders reported 18 open-market sales worth $3.9M and 2 purchases worth $5.7M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Panacea Innovation Ltd (10% owner), with $3.2M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Atara Biotherapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ATRA

35 funds and institutions reported ATRA shares worth $51.3M at the end of Q2 2026, about 55% of the company. The largest holder is EcoR1 Capital, LLC with 19.0%.

Funds and institutions (13F) 55%Everyone else 45%

10 largest owners, by share of the company

EcoR1 Capital, LLC19.0%
Adage Capital Partners Gp, L.l.c.10.4%
Point72 Asset Management, L.P.8.4%
Redmile Group, LLC5.4%
Vanguard Capital Management LLC3.0%
Mackenzie Financial Corp2.9%
BlackRock, Inc.1.0%
Geode Capital Management, LLC0.9%
Staley Capital Advisers Inc0.6%
Vanguard Fiduciary Trust Co0.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
EcoR1 Capital, LLC1.55M18.98%$17.8M+1458%
Adage Capital Partners Gp, L.l.c.850,00010.39%$9.8M+21%
Point72 Asset Management, L.P.687,7188.41%$7.9M+254%
Redmile Group, LLC441,7015.40%$5.1MNo change
Vanguard Capital Management LLC247,0473.02%$2.8M+13%
Mackenzie Financial Corp233,2492.85%$2.7M-26%
BlackRock, Inc.84,4551.03%$970K+7%
Geode Capital Management, LLC75,1280.92%$863K+14%
Staley Capital Advisers Inc50,0000.61%$574KNo change
Vanguard Fiduciary Trust Co43,0360.53%$494K+28%
Acadian Asset Management LLC38,8450.47%$444K-70%
Jane Street Group, LLC30,3450.37%$348K-10%
State Street Corp26,4530.32%$304KNo change
Northern Trust Corp16,5910.20%$190K+34%
FMR LLC (Fidelity)16,2380.20%$186KNo change
XTX Topco Ltd15,3030.19%$176KNew
Bridgeway Capital Management, LLC14,0000.17%$161K-57%
Millennium Management LLC12,6800.16%$146K-73%
Citadel Advisors LLC10,1590.12%$117KNew
Morgan Stanley9,1780.11%$105K+0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ATRA insiders reported $5.7M of open-market purchases and $3.9M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$5.7M
2 trades, 2 people
Sales, 12 months
$3.9M
18 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 4, 2026
Filed Sep 4, 2026

Purchases and sales by month

$4.7M$4.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 4, 2026Brian N CherryDirectorPurchase104,166$9.60$1000KForm 4
Aug 17, 2026AnhCo NguyenCEOSale5,062$8.08$40.9KForm 4
May 18, 2026AnhCo NguyenCEOSale5,241$9.13$47.9KForm 4
May 18, 2026Yanina Grant-HuertaChief Accounting OfficerSale2,414$9.13$22KForm 4
May 7, 2026Panacea Innovation Ltd +110% ownerSale313,446$10.10$3.2MForm 4
May 7, 2026EcoR1 Capital, LLC10% ownerPurchase507,407$9.35$4.7MForm 4
Mar 2, 2026Yanina Grant-HuertaChief Accounting OfficerSale377$5.08$1.9KForm 4
Mar 2, 2026Yanina Grant-HuertaChief Accounting OfficerSale1,603$5.08$8.1KForm 4
Mar 2, 2026Yanina Grant-HuertaChief Accounting OfficerSale24$5.08$122Form 4
Mar 2, 2026Yanina Grant-HuertaChief Accounting OfficerSale100$5.08$508Form 4
Mar 2, 2026AnhCo NguyenCEOSale58$5.08$295Form 4
Mar 2, 2026AnhCo NguyenCEOSale1,298$5.09$6.6KForm 4
Mar 2, 2026AnhCo NguyenCEOSale198$5.08$1KForm 4
Mar 2, 2026AnhCo NguyenCEOSale1,442$5.09$7.3KForm 4
Jan 12, 2026James Huang +1DirectorSale80,554$6.07$489KForm 4
Nov 17, 2025AnhCo NguyenCEOSale56$13.19$739Form 4
Nov 17, 2025AnhCo NguyenCEOSale2,859$13.19$37.7KForm 4
Nov 17, 2025Yanina Grant-HuertaChief Accounting OfficerSale1,645$13.19$21.7KForm 4
Nov 17, 2025Yanina Grant-HuertaChief Accounting OfficerSale74$13.19$976Form 4
Nov 17, 2025Yanina Grant-HuertaChief Accounting OfficerSale85$13.19$1.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
EcoR1 Capital, LLC10% owner$4.7M–May 7, 2026
Panacea Innovation Ltd10% owner–$3.2MMay 7, 2026
Brian N CherryDirector$1000K–Sep 4, 2026
James HuangDirector, 10% owner–$489KJan 12, 2026
AnhCo NguyenPresident and CEO, Director–$142KAug 17, 2026
Yanina Grant-HuertaChief Accounting Officer–$56.5KMay 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ATRA short interest

Low short interest. 3.0% of ATRA shares are sold short: about 1 share in 34. Over the last 12 reports the number of shares short went down 46%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 296,651 ATRA shares were sold short, 3.0% of the shares outstanding, down 15.3% from the report before. At the average daily volume of 22,085 shares, buying them all back would take about 13.4 trading days (days to cover).

Shares short, % of all shares

2.96%May 15Oct 307.68%

Days to cover

13.4May 15Oct 3015.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026296,6512.96%-15%22,08513.4
Oct 15, 2026350,2603.49%+9%40,2638.7
Sep 30, 2026321,7923.21%-20%39,6578.1
Sep 15, 2026404,2704.03%-5%55,0577.3
Aug 31, 2026427,4354.26%-10%38,61911.1
Aug 14, 2026477,2684.75%-11%51,8429.2
Jul 31, 2026536,8976.57%-7%57,1669.4
Jul 15, 2026577,6357.06%+60%92,5306.2
Jun 30, 2026361,5204.42%-27%91,5054.0
Jun 15, 2026492,4056.02%+2%78,5546.3
May 29, 2026484,3915.92%-11%166,2372.9
May 15, 2026546,4706.68%+79%7.39M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Atara Biotherapeutics company events

Atara Biotherapeutics filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026ResultsReleased financial results. Filing
  3. Jun 26, 2026LeadershipAtara Biotherapeutics, Inc. notified Yanina Grant-Huerta, the Company’s Chief Accounting Officer, that her employment with the Company would end effective July 17, 2026. Filing
  4. Jun 12, 2026LeadershipThe Board of Directors of Atara Biotherapeutics, Inc. appointed Brian Cherry to serve as a member of the Board as a Class I director, effective June 11, 2026. Filing
  5. May 7, 2026AnnouncementAtara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” providing an update following the Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter for the EBVALLO™ Biologics License… Filing
  6. May 1, 2026ListingAtara Biotherapeutics, Inc. received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the Company no longer meets Nasdaq’s $50 million minimum market value for listed securities requirement pursuant to Nasdaq Listing Rule 5450(b)(2)(A)… Filing
  7. Mar 16, 2026ResultsReleased financial results. Filing
  8. Mar 12, 2026AnnouncementAtara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” announcing that the Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter for the EBVALLO™ Biologics License Application issued… Filing
  9. Mar 3, 2026AnnouncementAtara Biotherapeutics, Inc. issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel” announcing that Pierre Fabre Pharmaceuticals, Inc. has submitted a request for a Type A meeting with the U.S. Food and Drug Administration to discuss the plan to address the… Filing
  10. Feb 23, 2026AgreementAtara Biotherapeutics, Inc., entered into an Amendment to the Purchase and Sale Agreement dated as of December 20, 2022 with HCR Molag Fund, L.P. Filing
  11. Jan 12, 2026AnnouncementBelow, on January 12, 2026, Atara Biotherapeutics, Inc. announced its cash, cash equivalents and short term investments as of December 31, 2025. Filing
  12. Jan 2, 2026AgreementAtara Biotherapeutics, Inc., entered into the Fourth Amendment to the Amended and Restated Commercialization Agreement dated October 31, 2023 with Pierre Fabre Medicament. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Atara Biotherapeutics financials

Famous investors that hold ATRA

2 of the 50 well-known investors we track reported holding ATRA in their latest 13F filing. The largest position is Steve Cohen's, worth $5.8M.

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 2026677,696$5.8M0.0%-1%
Ken Griffin · Citadel AdvisorsQ3 202643,079$366K0.0%+324%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Atara Biotherapeutics, Inc. (ATRA) stock

Who owns the most ATRA stock?

The largest reported owner of Atara Biotherapeutics, Inc. (ATRA) is EcoR1 Capital, LLC, with 19.0% of the company. In total, 35 funds and institutions reported holding ATRA at the end of Q2 2026, together about 55% of the shares. See the largest owners.

Are ATRA insiders buying or selling?

In the last 12 months, ATRA insiders reported 2 open-market purchases worth $5.7M and 18 sales worth $3.9M. The latest trade was on Sep 4, 2026. See every trade.

What is the short interest in ATRA?

As of Oct 30, 2026, 296,651 ATRA shares were sold short, 3.0% of the shares outstanding, down 15.3% from the report before. At the average daily volume of 22,085 shares, buying them all back would take about 13.4 trading days (days to cover). See the history.

Which famous investors hold ATRA?

2 of the 50 well-known investors we track reported ATRA in their latest 13F filing, including Steve Cohen, Ken Griffin. The largest position is worth $5.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.